The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
about
The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptorsA comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerolEndocannabinoids in the retina: from marijuana to neuroprotectionIdentification of intracellular carriers for the endocannabinoid anandamideSelectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profilingBrain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid systemMarijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalizationX-ray Crystallographic Analysis of α-Ketoheterocycle Inhibitors Bound to a Humanized Variant of Fatty Acid Amide HydrolaseReversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long-Acting AnalgesicsFatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disordersEnzymatic pathways that regulate endocannabinoid signaling in the nervous systemKeys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding PocketsRequirement for the endocannabinoid system in social interaction impairment induced by coactivation of dopamine D1 and D2 receptors in the piriform cortexRole of Cannabinoids in Gastrointestinal Mucosal Defense and InflammationLipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2.α-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain.The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).Quantification of brain endocannabinoid levels: methods, interpretations and pitfallsToward an anandamide transporter.Cannabinomimetic lipid from a marine cyanobacteriumThe decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ anIn vivo SPECT and ex vivo autoradiographic brain imaging of the novel selective CB1 receptor antagonist radioligand [125I]SD7015 in CB1 knock-out and wildtype mouse.Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.Lipidomic metabolism analysis of the endogenous cannabinoid anandamide (N-arachidonylethanolamide)Microwave Assisted Synthesis of Sodium Sulfonates Precursors of Sulfonyl Chlorides and Fluorides.Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent mannerEthyl 1-tert-butyl-5-phenyl-1H-pyrazole-4-carboxyl-ateEthyl 1,5-diphenyl-1H-pyrazole-4-carboxyl-ate.The preparation of 2-O-[1'-C]arachidonoyl-1-O-stearoyl-sn-glycerol.Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown.Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligandsEndocannabinoids and acute pain after total knee arthroplasty.Organic carbamates in drug design and medicinal chemistryActions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation.Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.α-Ketoheterocycle-based Inhibitors of Fatty Acid Amide Hydrolase (FAAH).Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic propertiesC3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptorCannabinoids: a new group of agonists of PPARs.
P2860
Q24602845-B3E0D679-127F-4F2F-B17D-D062EC2FAED7Q24649418-B25CC926-58B8-41F2-BFE6-F2511163EF20Q24656049-DF4662F0-85CE-4753-A583-E4E66267069DQ24658373-9D395991-8AF7-43CE-BEA5-48735CD21FB3Q24658561-F55B12AE-8365-4FA0-A1A0-A17C6CA50AD6Q26865295-58A2C26D-38F7-4841-B547-88987E06B384Q27009287-26ADACAC-A6D3-47DD-A156-F71FF5164794Q27658264-5AE20DC4-0E13-4C5C-885A-455284C985BDQ27667312-A600DB7A-1552-4758-A1CF-2464657219DFQ28285103-2EB94928-2F34-4573-9662-7CDF5B8BC70DQ28390932-4912AA02-03C2-40E5-8FAE-3913F9463575Q28548681-07B8C623-5D8B-4CE5-8CEE-3F0A2D5820B6Q28581295-8C5EF374-AE0F-41DF-B407-253C29987EDBQ30357558-669E3789-2729-4F24-8B95-92CFADD09FFEQ33594073-1BD1DB9B-1B18-40B7-8EA7-838FE3C24EC8Q33644120-DF0FD66E-4827-46F0-904F-A643802E7FA7Q34027721-5791FA9C-804D-4686-8DE7-3EE3A988C85BQ34098167-C053719D-8B9B-491A-B6E9-AA3978A18877Q34201946-F47D3FBA-E6F9-4E68-A123-8AA6124586C2Q34224331-ECF95B57-FC40-4F6B-A354-27D83C44FD29Q34267133-F080B88F-48A8-475F-9150-9054D4067F68Q34278947-0E85CADC-4D4F-45AE-B6C1-879858E1DDE3Q34278963-2E60F300-D394-4CCE-BF8A-BB60C8905505Q34282147-1F159C1F-2E2A-4E70-B3FF-CA1063C8751CQ34363783-FBC065DE-1B92-45BB-AB42-9B397B608DA9Q34422088-4BF9A273-0923-401A-BCEC-0EDD76459DA4Q34431112-BFF34E88-20A3-4486-A14D-1135B38467AAQ34431683-1EF7FD9F-95BF-48B5-A372-C4F0DC791735Q34680798-797FC957-FBFB-40B7-9A4D-BCCA157C8BD5Q34818110-12FB11B0-F6E1-495A-B243-45F0DBFFC5AEQ34841008-970BEEA3-1440-4220-A621-9696F3C0A7A0Q34988278-0A93C446-F856-40C8-A940-BF306D9E2426Q35365543-8B647729-AAA4-4B7C-A2F5-64F8B2A2ED34Q35545219-764D8285-9154-4D04-A918-E3407DE17BCFQ35645037-909E0CA1-762D-43D8-8D03-DF530AEB33D4Q35689152-E9DB83EA-9363-4973-A1F6-70E9B538CAE1Q35986269-BD72ABB7-F7B4-4D18-AD5F-7C8C855793B6Q36003998-EE783B50-A73C-4FD2-BA5A-EFD4842F5F97Q36243317-F03747D2-07E9-480F-8F14-5E81301F7797Q36417528-41431270-29F5-4B00-B107-531D5BB64AE5
P2860
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The endocannabinoid system: dr ...... tial therapeutic applications.
@ast
The endocannabinoid system: dr ...... tial therapeutic applications.
@en
The endocannabinoid system: dr ...... tial therapeutic applications.
@nl
type
label
The endocannabinoid system: dr ...... tial therapeutic applications.
@ast
The endocannabinoid system: dr ...... tial therapeutic applications.
@en
The endocannabinoid system: dr ...... tial therapeutic applications.
@nl
prefLabel
The endocannabinoid system: dr ...... tial therapeutic applications.
@ast
The endocannabinoid system: dr ...... tial therapeutic applications.
@en
The endocannabinoid system: dr ...... tial therapeutic applications.
@nl
P356
P1476
The endocannabinoid system: dr ...... tial therapeutic applications.
@en
P2093
Christopher J Fowler
Didier M Lambert
P304
P356
10.1021/JM058183T
P407
P577
2005-08-01T00:00:00Z